Assessment of patient-reported outcomes at 24 weeks of treatment with tralokinumab for atopic dermatitis: a multicentric real-life experience

Bibliographic Details
Published in:	Journal of Dermatological Treatment
Main Authors:	Silvia Ferrucci, Francesca Barei, Simona Tavecchio, Angelo V. Marzano, Martina Zussino, Luigi Naldi, Elena Pezzolo
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Online Access:	https://www.tandfonline.com/doi/10.1080/09546634.2023.2285243

Similar Items

Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients
by: Francesca Barei, et al.
Published: (2024-01-01)

Five-year real-world drug survival of dupilumab in severe atopic dermatitis and associate predictors
by: Francesca Barei, et al.
Published: (2024-12-01)

Emerging Systemic Treatments for Atopic Dermatitis
by: Silvia Mariel Ferrucci, et al.
Published: (2023-04-01)

Preliminary experience with abrocitinib in severe atopic dermatitis
by: Silvia Ferrucci, et al.
Published: (2024-06-01)

Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab
by: Annunziata Dattola, et al.
Published: (2024-07-01)

Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
by: Fabrizio Martora, et al.
Published: (2024-12-01)

Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals
by: Giovanni Paolino, et al.
Published: (2024-12-01)

Mycosis fungoides unmasked by tralokinumab treatment for atopic dermatitis
by: Sanah Basrai, BA, et al.
Published: (2025-07-01)

Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations
by: Potestio L, et al.
Published: (2024-08-01)

Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study
by: Laura Calabrese, et al.
Published: (2025-03-01)

Asthma improvement in patients treated with dupilumab for severe atopic dermatitis
by: Marco Dubini, et al.
Published: (2023-09-01)

Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis
by: Steven J Edwards, et al.
Published: (2024-01-01)

Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis
by: Galina Balakirski, et al.
Published: (2023-12-01)

Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study
by: Tiago Torres, et al.
Published: (2025-06-01)

Real‐life case‐series experience with tralokinumab in patients with severe atopic dermatitis
by: Francesca Caroppo, et al.
Published: (2024-03-01)

Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
by: Tiago Torres, et al.
Published: (2024-04-01)

Correction: Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
by: Tiago Torres, et al.
Published: (2025-01-01)

Tralokinumab for moderate-to-severe atopic dermatitis: A viable option for dupilumab nonresponders
by: Christine T. Olagun-Samuel, BA, et al.
Published: (2026-02-01)

Effectiveness of Tralokinumab in Different Phenotypes of Atopic Dermatitis: A Real-World Study
by: Ersilia Tolino, et al.
Published: (2025-01-01)

Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience
by: Luigi Gargiulo, et al.
Published: (2023-12-01)

Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis
by: L. Mastorino, et al.
Published: (2023-12-01)

Atopic dermatitis: real-life experience with tralokinumab after dupilumab failure: a case series
by: Patrícia Amoedo, et al.
Published: (2024-09-01)

Clinically Meaningful Improvements in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab who did not Achieve Clear or Almost Clear Skin at Week 16
by: Amy S. Paller, et al.
Published: (2025-07-01)

Association of Tralokinumab and Adalimumab: Good Tolerance and Efficacy in a Case of Severe Atopic Dermatitis and Juvenile Idiopathic Arthritis
by: F. Rakotonandrasana, et al.
Published: (2025-09-01)

[Pharmacoeconomic Comparison Between Dupilumab and Tralokinumab for the Treatment of Atopic Dermatitis in Italy: A Cost-per-Responder Analysis]
by: Paolo Gisondi, et al.
Published: (2025-05-01)

Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data
by: Kaidi Zhao, et al.
Published: (2024-08-01)

Tralokinumab as an Alternative to Dupilumab in a Patient with Atopic Dermatitis and Asthma who Developed Hypereosinophilia: A Case Report
by: Ilaria Trave, et al.
Published: (2024-09-01)

The Tralokinumab Pre-Filled Pen Improved Atopic Dermatitis Signs and Symptoms and Was Well Tolerated in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 16-Week, Open-Label, Single-Arm Phase 3 Study (INJECZTRA)
by: Jennifer Soung, et al.
Published: (2025-07-01)

Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review
by: Lauletta G, et al.
Published: (2025-01-01)

Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis)
by: Luigi Gargiulo, et al.
Published: (2024-12-01)

Real‑World Experience of 1 Year of Tralokinumab Treatment in Adult Patients with Atopic Dermatitis: A Single-Center Retrospective Study
by: Adrian O. Rodriguez, et al.
Published: (2025-06-01)

JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis)
by: Mariateresa Rossi, et al.
Published: (2025-07-01)

Safety and Effectiveness of Dupilumab in Atopic Dermatitis Patients with Hematologic Comorbidities: A Multicenter, Retrospective Study
by: Luca Bettolini, et al.
Published: (2025-09-01)

Abrupt Bullous Cutaneous Eruption After Application of Tacrolimus Ointment and Sun Exposure
by: Cristina Beatrice Spigariolo, et al.
Published: (2023-07-01)

Correction: The role of interleukin-24 in atopic dermatitis
by: Editorial Office
Published: (2024-11-01)

Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis
by: Ana Batalla, et al.
Published: (2023-09-01)

Long-Term Efficacy and Potential Predictors of Tralokinumab Dose Optimization in Elderly Patients: A Multicentre Study
by: Francisco Javier Melgosa Ramos, et al.
Published: (2025-04-01)

Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience
by: Luigi Gargiulo, et al.
Published: (2023-12-01)

Predictors for the Efficacy of 4-Week Dupilumab Treatment in Atopic Dermatitis Patients
by: Yu L, et al.
Published: (2025-03-01)

A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis
by: Paolo Amerio, et al.
Published: (2024-05-01)